Likewise, in vivo treatment with CXCR4 antagonists reduced intratibial growth and tumor-induced osteolysis of PC3 cells, whereas overexpression of CXCR4 increased PC3 tumor growth in bone and osteolysis (76, 79, 80). Here, CXCR4 is linked to neoplasm.